Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Type 3 inflammation–specific keratinocyte glutaminolysis promotes skin inflammation
Yongfei Hu, Hai Yu, Kaiyu Liang, Liyan Yuan, Wenjun Zhang, Zhe Zhuang, Suyun Ji, Xichun Xia
Yongfei Hu, Hai Yu, Kaiyu Liang, Liyan Yuan, Wenjun Zhang, Zhe Zhuang, Suyun Ji, Xichun Xia
View: Text | PDF
Research Article Dermatology Metabolism

Type 3 inflammation–specific keratinocyte glutaminolysis promotes skin inflammation

  • Text
  • PDF
Abstract

Inflammatory cytokines reprogram keratinocyte metabolism, but the metabolic pathways that couple immune signals to pathological epidermal growth remain incompletely defined. Here, we identify glutaminase 1–mediated (GLS1-mediated) glutaminolysis as a metabolic program preferentially induced in keratinocytes under type 3 inflammatory conditions. Integrated transcriptomic, metabolomic, genetic, and functional analyses showed that IL-17A induced GLS1 expression and glutaminolysis in keratinocytes. Keratinocyte-specific Gls1 deletion reduced the intracellular availability of arginine, proline, and methionine, impaired amino acid–dependent mTORC1 activation, disrupted redox homeostasis, and limited keratinocyte proliferation. Amino acid or antioxidant supplementation partially rescued these defects, whereas rapamycin blocked the amino acid–mediated proliferative rescue. Gls1 deletion did not impair steady-state skin development or homeostasis and did not alter MC903-induced type 2 dermatitis, but it delayed wound re-epithelialization and attenuated imiquimod-induced psoriasiform inflammation. Loss of keratinocyte GLS1 also reduced epidermal chemokine expression and the accumulation of neutrophils and IL-17A–producing γδ T cells, revealing a role for glutaminolysis in amplifying epithelial-immune crosstalk. These findings define GLS1-mediated glutaminolysis as a context-specific metabolic checkpoint linking type 3 inflammation to keratinocyte proliferation and cutaneous immune amplification, and support locally or temporally controlled GLS1 inhibition as a potential therapeutic strategy for psoriasis.

Authors

Yongfei Hu, Hai Yu, Kaiyu Liang, Liyan Yuan, Wenjun Zhang, Zhe Zhuang, Suyun Ji, Xichun Xia

×

Figure 3

GLS1 maintains amino acid pools and redox homeostasis to support mTORC1 activation and keratinocyte proliferation.

Options: View larger image (or click on image) Download as PowerPoint
GLS1 maintains amino acid pools and redox homeostasis to support mTORC1 ...
(A and B) LC-MS/MS analysis of differential metabolites in IL-17A–treated primary basal keratinocytes isolated from cKO versus WT mice (n = 4). Top 10 significantly enriched KEGG pathways of differential metabolites (A), and heatmap of top 20 significant differential metabolites (B) between WT and cKO keratinocytes. (C and D) Transcriptome analysis of DEGs in IL-17A–treated primary basal keratinocytes isolated from cKO versus WT mice (n = 3). GSEA of amino acid metabolism (C) and amino acids that regulate mTORC1 (D) based on metabolism-related DEGs between WT and cKO keratinocytes with IL-17A treatment. (E and F) Primary basal keratinocytes isolated from WT and cKO mice were treated with IL-17A and an amino acid mixture (arginine, proline, and methionine) rescue (AA1, 1 mM; AA2, 2 mM) or not (n = 3). Western blot for mTORC1 activation (E) and crystal violet staining for proliferation (F) of WT and cKO basal keratinocytes with and without amino acid supplementation. (G and H) Effects of rapamycin on amino acid–mediated restoration of mTORC1 signaling and cell growth. (I) GSEA of glutathione metabolism based on metabolism-related DEGs between WT and cKO basal keratinocytes with IL-17A treatment (n = 3). (J) RT-PCR measurement of oxidative stress–related genes in WT and cKO basal keratinocytes with IL-17A treatment (n = 3). (K) FACS analysis of the fluorescence after DCFDA staining of WT and cKO basal keratinocytes with IL-17A treatment (n = 4). (L) Crystal violet staining for proliferation (F) of WT and cKO basal keratinocytes with and without glutathione (GSH) or N-acetyl-cysteine (NAC) supplementation (n = 3). Data are presented as mean ± SD and representative of 3 independent experiments with consistent results. Statistical significance was determined by 1-way ANOVA with Tukey’s multiple-comparison test (F, G, and L) or 2-tailed Student’s t test (J and K). *P < 0.05; **P < 0.01; ***P < 0.001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts